Elephas Live™ Platform
Elephas Live™ Platform: Ex vivo cytokine profiling enables precision medicine
Receive your quote directly from the manufacturer.
Elephas has developed a functional ex vivo platform that measures cytokine response in live tumor biopsies following treatment with a therapeutic agent. These insights will help you:
- Prioritize therapeutic candidates for clinical development
- Identify patient profiles to inform trial strategies
- Identify combinations and comparisons
- Identify potential biomarkers
- Explore opportunities for future companion diagnostics
If you're interested in learning about how the Elephas Live™ Platform could accelerate your IO pipeline, contact us on https://landing.elephas.com/pharma
Encapsulation of live tumor fragments in Elephas Live Protect preserves the native tumor microenvironment during ex vivo culture
In this white paper, Elephas Biosciences presents data demonstrating that Elephas Live™ Protect, a proprietary hydrogel and element of the Elephas Live™ Platform, preserves features of the native tumor microenvironment (TME) in live tumor fragments (LTFs) during ex vivo culture.
A method for preparing tumor tissues for ex vivo culture that retains T cells within live tumor fragments (LTFs) while preserving tissue viability and T cell function
Traditional tissue preparation methods can disrupt the tumor microenvironment (TME), which poses challenges for characterizing responses to immunotherapy in live tumor fragments (LTFs).
In this scientific poster, Elephas Biosciences presents a method that incorporates automated cutting instruments designed to optimally fragment tumor resections and core needle biopsies (CNBs), and a proprietary hydrogel that supports the TME of LTFs in ex vivo culture.
TechTalk: Improving predictions in immunotherapy treatment
Friday, January 30 at 15:30 GMT | 16:30 CET | 10:30 EST | 7:30 PST
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, today there is no reliable way to determine which immunotherapy a cancer patient will respond to with current biomarkers lacking predictive accuracy.
Dr. Hinco J. Gierman, Chief Scientific Officer, Elephas Biosciences, will share the predictive power of the Elephas Live™ Platform. This platform utilizes fresh tumor biopsies that are cut and encapsulated to be assessed for viability, tumor content, and response to immunotherapy over time.
Attend this TechTalk, and in just 20 minutes, you will discover how live tumor cytokine profiling can improve decision making and capture data non-destructively all within 72 hours of taking the biopsy.
Key learning objectives:
- Discover how to de-risk pipeline decisions with real-time immune response data
- Optimize trial design through functional profiling and biomarker validation
- Learn how to accelerate candidate therapeutic development by identifying likely responders to your treatment earlier
Who should attend?
- Pharma and biotech executives responsible for clinical pipeline development, search and evaluation, and licensing.
- Internal pharma leaders (CSO, CMO, clinical biomarker leaders, and trial directors).
Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.
